Showing posts with label complete response. Show all posts
Showing posts with label complete response. Show all posts

February 2, 2014

Big Pharma has a Shrinkage Problem

Big Pharma can't kill tumors. “We are pretty good at shrinking tumors, but not good at getting rid of them. Immune therapy is a way to begin to approach that.” -- Merck senior vice president Gary Gilliland (from an article by Robert Langreth on May 12, 2013)

I think most people would agree killing tumors should go a long way in fighting, arresting and perhaps even killing cancer. Medical literature discusses the positive correlation between complete response -- the tumor, after treatment, goes away -- and overall survival, "...the gold standard primary end point to evaluate the outcome of any drug, biologic, intervention, or procedure that is assessed in oncologic clinical trials."

Big Pharma is making process. Stabilizing the disease, by preventing the further growth of cancerous tumors, is good. Shrinking them is better.

Killing them is best.

While Big Pharma's oncology drugs and drug candidates are increasingly demonstrating better overall responses (or overall response rates), complete response plus partial response (shrinking the tumor), it's struggling to improve complete response (killing the tumor).
Click to enlarge the table
And it doesn't look like Big Pharma will solve the problem of killing tumors -- achieve better complete responses -- anytime soon, because it appears pharmaceutical companies are hitting a ceiling for complete response.

From my November 23, 2013 post [We] now believe...[we] have sufficient information to seek regulatory approval: I read an interesting abstract at the 2013 Society for Immunotherapy of Cancer ("SITC") Annual Meeting, co-authored by Martin Ashdown and Provectus principal investigator Brendon Coventry: Mathematical modeling of immune kinetics in advanced cancer through meta-analyses of complete response rates: immune synchronisation emerges as the likely key determinant of clinical response. Ashdown et al.'s work comprised a meta-analysis of 130 clinical trials, 8,000 patients, different solid tumor cancers, and standard chemotherapy, targeted therapy and iimmunomodulatory therapy compounds IL-2, ipilimumab, tremelimumab, cytotoxic agents, TMZ, dabrafenib, vemurafenib, PD-1s (BMS, Merck) and a PDL-1 (Genentech).
Click to enlarge the table
Ashdown and Conventry concluded:"Mathematical analyses of over 130 clinical trials, inclusive of over 8000 patients, has demonstrated that the CR rate for patients treated with widely divergent therapies is remarkably fixed at between 5 and 10%. The probability of this occurring by chance alone is extremely close to zero, and is both scientifically and clinically implausible. Therefore, an underlying predictive operative biological mechanism must apply. It is highly likely that the known principles of immune kinetics between effector and regulatory homeostatic functions must therefore determine a degree of immune synchronization to produce these observed CR’s. We have derived a mathematical model and equation using the principles of controlled homeostatic systems, which can be used to explain our meta-analysis findings, and the clinical efficacy." Bold and underlined emphasis is that of Ashdown et al. from their SITC poster presentation.

May 17, 2013

Big Pharma: "We are pretty good at shrinking tumors, but not good at getting rid of them."

Houston, Big Pharma has a problem. Lots of drug candidates, and lots of shrinking. But Big Pharma still cannot get rid of cancer tumors.

A blog reader forwarded me Dr. Sally Church PhD's post on ASCO 2013 highlights of PD-1 and PDL-1 immunotherapy, which are capturing media attention. Thank you. Her key points include (a) too much focus on overall respons rate (ORR), (b) ORR is a measure of disease control, not disease cure or a measure of response durability, (c) being sure to compare apples to apples when examining these ASCO abstract results, and (d) ORR not being an ideal endpoint, but rather how long do patients live, do they feel better and do they have a better quality of life.

ORR = CR + PR. Overall response rate equals complete response plus partial response. From RECIST criteria, CR (complete response) = disappearance of all target lesions, and PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions.

PV-10's clinical value proposition is very simple: Very safe. Very efficacious (effective). Very useful (on many different solid tumor cancers).

Key, within this value proposition, are how high CR is -- the elimination of tumors, not merely the shrinkage of them -- and the durability of the response to PV-10 -- one the tumors are eliminated, they don't come back. Thus, PV-10's more nuanced value proposition: Permanent elimination.

Only shrinking tumors, but not fully eliminating them, has the effect of allowing resistance to build up to drug treatment. Harnessing the immune system to turn tumor heterogeneity on its head is facilitated by tumor elimination.

Other historical therapies -- from the previous standard of care of DTIC to anti-CTLA-4 agents like treme and ipi to intralesional therapies immunotherapies like Allovectin-7 and OncoVex (T-Vec or talimogene laherparepvec) to emerging immunotherapies like anti-PD-1 and anti-PDL-1 agents -- do not have the complete response of tumors that PV-10 generates.



In the Phase 2 trial, there was an 80% treatment success rate of individual lesions with an associated complete response ("CR") of more than 50%. Think of a set of data comprising all lesions treated, irrespective of patient. Success was achieved in 80% of these datapoints. 80% success was achieved despite limited treatment (i.e., 1 initial injection and up to 3 additional injections), physician error while injecting lesions (i.e., some lesions were improperly injected), patients and their lesions left the trial, and patients with compromised immune systems and ravaged bodies from failed prior treatments had their lesions injected.

Final results of patients included: